On the device regulatory front, 2014 was not a year of fireworks like, say, 2009 (think CDRH whistleblowers) or 2012 (think user fee reauthorization in Congress). For FDA premarket review performance, it was in many ways a year of validation and documentation – with the agency and the device industry meticulously, but, for the most part, respectfully, watching each other and watching the data to ensure their carefully crafted user-fee agreement remains a net-benefit for both sides. "The Gray Sheet" was closely watching too.
Early signs are generally positive, with backlogs of 510(k) and PMA submissions, both at record highs several years ago, dropping precipitously, and overall review times showing some promising trends. (See...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?